MDMA-enhanced couples therapy shows promise for treating PTSD and relationship distress

New research suggests that pairing a brief form of couples therapy with MDMA can lead to large improvements in posttraumatic stress disorder symptoms and relationship satisfaction for veterans and their partners. The preliminary findings, published in Journal of Traumatic Stress, provide evidence that these benefits occur even when only the diagnosed veteran receives the medication.

Posttraumatic stress disorder, commonly known as PTSD, is a mental health condition triggered by experiencing or witnessing a terrifying event. Symptoms tend to include flashbacks, nightmares, and severe anxiety. Beyond the individual, PTSD often strains close relationships, undermining communication and a sense of safety between partners.

Veterans are particularly at risk for PTSD due to the stressors of military deployment. Their intimate partners frequently experience secondary effects, leading to elevated rates of relationship distress. To address both the individual symptoms and the relational strain, psychologists developed cognitive-behavioral conjoint therapy. This is a type of talk therapy where the person with PTSD and their partner attend sessions together to learn how trauma impacts relationships, how to communicate better, and how to challenge unhelpful trauma-related thoughts.

While this therapy is effective at reducing PTSD symptoms, its ability to improve overall relationship satisfaction tends to be moderate. The brief, eight-session version of this therapy is similarly effective for PTSD but produces even smaller relationship gains.

To boost the relationship benefits, researchers have been looking into MDMA, a psychoactive drug that alters mood and perception. In a clinical setting, MDMA is thought to promote empathy, social connection, and a reduction in fear. For instance, a 2026 trial analysis found that MDMA combined with psychotherapy helps relieve chronic PTSD symptoms, with patients experiencing positive mood changes that aid in their recovery.

Free daily newsletter

A previous study tested the full cognitive-behavioral conjoint therapy protocol paired with MDMA, but it gave the medication to both partners. The research team behind the new study, led by Leslie A. Morland at the Department of Veterans Affairs National Center for PTSD, recognized that prescribing MDMA to a partner who does not have PTSD is likely impractical under future medical and insurance guidelines. They designed their study to see if providing a brief version of the therapy, and giving MDMA solely to the veteran diagnosed with PTSD, could still yield both individual and relational benefits.

The researchers recruited eight couples from the Veterans Affairs San Diego Healthcare System. In each couple, the veteran met the diagnostic criteria for PTSD, while the partner did not. The veterans had an average age of about 46, and the partners had an average age of roughly 43.

The treatment program lasted about seven weeks. It involved the eight-session brief cognitive-behavioral conjoint therapy protocol, but added two day-long MDMA dosing sessions for the veteran. Before the first MDMA session, the couples attended an introductory preparation session.

During the first MDMA session, the veteran was administered an initial dose of 80 milligrams of MDMA, with an optional 40-milligram supplemental dose a few hours later. The second session involved a higher initial dose of 100 milligrams, also with an optional 40-milligram supplement. The partner was invited to join the room for the final one to two hours of these MDMA sessions to connect and share, though they did not receive the drug themselves.

On the morning following each MDMA session, the couple attended an integration session. During these meetings, the veteran shared their experiences and insights from the medication session, and the partner shared their emotional responses. The therapists incorporated strategies from another evidence-based practice, integrative behavioral couple therapy, to help the partners build empathy and shift out of rigid conflict patterns.

The researchers measured outcomes using clinical interviews for PTSD severity and self-report questionnaires for relationship satisfaction. They tracked scores at the start of the study, during the treatment, at the end of the treatment, and at three and six months afterward. When analyzing the results, the researchers controlled for the initial baseline levels of the outcome variables to better isolate the effects of the treatment.

The veterans began the study with an average PTSD severity score of 39.1 on a standard clinical assessment scale, which ranges from 0 to 80. By the end of the treatment, the veterans showed a large drop in symptom severity, with an average decrease of 16.1 points.

Five of the eight veterans demonstrated a clinically meaningful treatment response. Among those five, three no longer met the diagnostic criteria for PTSD, and two achieved full symptom remission by the end of the study.

Relationship satisfaction also improved for both members of the couple. Veterans saw their relationship satisfaction scores increase by an average of 27.9 points on a questionnaire that measures relationship happiness and quality. The partners experienced an average score increase of 19.8 points.

Out of the six veterans and six partners who started the study with scores indicating clinical relationship distress, four veterans and four partners reached the non-distressed range by the end of treatment. One partner who started in the non-distressed range did experience a decline in relationship satisfaction over the course of the study.

In the follow-up period three and six months later, the researchers noted a slight rebound in PTSD symptoms, with average scores creeping up by about 6.3 points. Relationship satisfaction scores also retreated moderately during this time, though they remained better than the initial baseline scores.

The treatment was generally well-tolerated. No serious adverse events were reported. The most common side effects from the MDMA sessions included headaches, feeling warm, temporary increases in blood pressure, and nausea. All couples completed the full course of treatment, suggesting the program was acceptable and manageable for the participants.

“The key word is assisted: MDMA did not replace psychotherapy here,” Mitch Earleywine, a professor of psychology at the University at Albany, SUNY, who was not involved in the research, told PsyPost. “The team embedded two MDMA sessions within an established, empirically supported couples treatment for PTSD, and that combination produced substantial improvements in both PTSD symptoms and relationship satisfaction.”

Earleywine noted that the new results build on previous work by evaluating the medication within an already proven clinical framework. “The findings extend earlier evidence that both MDMA-assisted therapy and cognitive-behavioral conjoint therapy can help PTSD,” he said. “I especially like seeing researchers test MDMA as an adjunct to a treatment that already has a strong empirical foundation rather than pairing the drug with a loosely defined supportive therapy.”

“Readers should not come away thinking that two doses of MDMA treated PTSD or repaired these relationships,” Earleywine added. “Participants received a substantial course of structured couples therapy, preparation, integration, and clinical support, so the study tested MDMA-assisted psychotherapy rather than MDMA alone. I don’t want people thinking that tripping at a rave as a couple is gonna do anything substantial. These couples really put in a ton of work.”

As with all research, there are a few caveats to consider. The study was a pilot trial with a very small sample of only eight couples. Because there was no control group that received the therapy without MDMA or with a placebo, it is difficult to know exactly how much of the improvement was due directly to the medication versus the intensive therapy itself.

“I find the results encouraging but, as they emphasize, preliminary because the study included only eight couples and no control condition,” Earleywine said. To clearly map the drug’s role in the recovery process, he pointed out that future projects will need to isolate its effects. “I’d most like to see a randomized trial comparing this same couples treatment with and without MDMA. That design could tell us whether MDMA adds meaningful benefit to an already effective treatment, and whether any added gains justify the extra cost, time, and medical infrastructure.”

The study participants were predominantly white, heterosexual, and highly educated. This means the findings might not apply to couples with different demographic backgrounds or those with less access to resources.

The partial return of symptoms and relationship distress during the follow-up months indicates that an eight-session therapy model might not be enough to produce permanent changes for everyone. Veterans with complex psychiatric histories might need longer treatment or extended integration support to maintain their initial gains.

Despite the constraints, Earleywine views the pilot program as a strong foundation for future research. “These effect sizes are really impressive. Folks really improved in an efficient way,” he said. “I’d love to think that my tax dollars are paying for something like this.”

The study, “Healing together: Results from a pilot trial of 3,4-Methylenedioxymethamphetamine-enhanced cognitive-behavioral conjoint therapy for posttraumatic stress disorder,” was authored by Leslie A. Morland, Chandra E. Khalifian, Dimitri Perivoliotis, Bettye Chargin, Al Alam, Tamara R. Wachsman, Dhakshin Ramanathan, Andrew W. Bismark, Christopher Stauffer, Anne C. Wagner, Abigail C. Angkaw, and Kayla C. Knopp.